Ashwagen® shows efficacy in managing stress and anxiety in hypertensive patients
A Phase III trial demonstrated that Ashwagen® significantly reduced anxiety and stress markers in patients with hypertension.
Asset / Drug
Drug and asset intelligence for Psychiatry with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.